| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
SUCNR1 (succinate receptor 1, GPR91). SUCNR1-IN-1 is an inhibitor of the human succinate receptor (hSUCNR1), with an reported IC50 of 88 nM. Its mechanism of action is likely competitive antagonism, blocking the binding of the endogenous ligand succinate to the receptor.
|
|---|---|
| ln Vitro |
SUCNR1-IN-1 demonstrates potent inhibitory activity against human SUCNR1 (hSUCNR1) with an IC50 of 88 nM in a cell-based functional assay. No specific in vivo activity data is reported, but the compound has potential for research into SUCNR1-mediated conditions as an inhibitor tool.
|
| Enzyme Assay |
A cell-free radioligand binding assay can be employed. Membranes from cells overexpressing SUCNR1 are incubated with a radiolabeled high-affinity antagonist (e.g., [3H]NF-56-EJ40) and varying concentrations of unlabeled SUCNR1-IN-1. Bound and free radioligand are separated by filtration, and the radioactivity is counted to determine inhibition constant (Ki) values.
|
| Cell Assay |
A typical cell-based functional assay for SUCNR1 is performed using CHO-K1 cells stably expressing human SUCNR1. Cells are seeded and loaded with a fluorescent calcium indicator (e.g., Fluo-4). Cells are then pre-incubated with various concentrations of SUCNR1-IN-1 followed by stimulation with succinate. The antagonist's IC50 is determined by measuring the reduction in intracellular calcium flux.
|
| Animal Protocol |
Not reported. Based on its profile as a small molecule inhibitor, in vivo studies would likely involve administration in rodent models of disease. For example, in a model of liver fibrosis, the compound could be administered daily via oral gavage for several weeks, and endpoints such as liver hydroxyproline content and collagen deposition would be assessed.
|
| ADME/Pharmacokinetics |
Not reported. As a research compound in early-stage discovery, its ADME (Absorption, Distribution, Metabolism, Excretion) properties are not publicly available. Its molecular structure suggests it could be optimized for oral bioavailability.
|
| Toxicity/Toxicokinetics |
Not reported. No toxicology data is available for SUCNR1-IN-1, as it is a tool for target validation. Its IC50 of 88 nM, while potent, is moderate, suggesting a wide therapeutic window might be achievable.
|
| References | |
| Additional Infomation |
SUCNR1 is a metabolite-sensing GPCR that is activated by succinate, a metabolite of the TCA cycle that accumulates in inflammatory and ischemic tissues. By inhibiting this receptor, SUCNR1-IN-1 can help elucidate its role in immune cell chemotaxis, renal hypertension, and retinal angiogenesis. As an early-stage research inhibitor, it is a starting point for developing more potent and drug-like antagonists for clinical use.
|
| Molecular Formula |
C26H22CLF3N2O4
|
|---|---|
| Molecular Weight |
518.912096500397
|
| Exact Mass |
518.122
|
| CAS # |
2711753-52-3
|
| PubChem CID |
154585554
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
36
|
| Complexity |
765
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1C[C@H](CNC1)OC2=C(C=C(C(=C2)C3=C(C(=CC=C3)C(=O)NC4=C(C=C(C=C4)F)CC(=O)O)F)F)Cl
|
| InChi Key |
MOOARNYDOKGVQG-MRXNPFEDSA-N
|
| InChi Code |
InChI=1S/C26H22ClF3N2O4/c27-20-12-21(29)19(11-23(20)36-16-3-2-8-31-13-16)17-4-1-5-18(25(17)30)26(35)32-22-7-6-15(28)9-14(22)10-24(33)34/h1,4-7,9,11-12,16,31H,2-3,8,10,13H2,(H,32,35)(H,33,34)/t16-/m1/s1
|
| Chemical Name |
2-[2-[[3-[4-chloro-2-fluoro-5-[(3R)-piperidin-3-yl]oxyphenyl]-2-fluorobenzoyl]amino]-5-fluorophenyl]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9271 mL | 9.6356 mL | 19.2712 mL | |
| 5 mM | 0.3854 mL | 1.9271 mL | 3.8542 mL | |
| 10 mM | 0.1927 mL | 0.9636 mL | 1.9271 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
